Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...

1 Departments of Family Medicine and Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, USA 2 Department of Family Medicine, University of Washington, Seattle, Washington ...

Department of Family Medicine, University of Washington, Seattle, Washington, USA Correspondence to Professor Jonathan A Drezner, Department of Family Medicine, University of Washington, P.O. Box ...

A young man with sickle cell disease (SCD) arrives at a New York City emergency department gripped by excruciating pain, the most common complication of SCD. He is seen—but not believed. Effective ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

More than half of Ohio’s small businesses survive five years, placing the state among the nation’s leaders, according to a new study. Data from the Bureau of Labor Statistics, analyzed by Ringy.com, ...

A Virginia man used both his bad and good luck for the day by crashing near a cardiologist’s office after having a heart attack. The Virginia Beach local has been given a second chance at life thanks ...

Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of participants with severe sickle cell disease. The therapy led to substantial ...

We earn a commission for products purchased through some links in this article. ©2025 Hearst UK is the trading name of the National Magazine Company Ltd, 30 Panton ...